Abstract
Prostate cancer is the most common cancer in men. Strategies relying on androgen deprivation have long been utilized in it’s treatment. However, the therapy of castration-resistant disease still remains challenging. Therapeu-tic options have rapidly evolved during the last decade. New molecules with unprecedented activity, provided significant survival benefit in advanced disease. This review presents the key aspects of prostate cancer systemic therapy evolution over the last decades. The first part focuses on therapies active in castration-resistant disease. Part two reviews data on earlier therapy lines and principles relevant to devising optimal treatment sequence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
